Atea Pharmaceuticalsinc Stock Alpha and Beta Analysis
| AVIR Stock | USD 3.71 0.03 0.80% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Atea PharmaceuticalsInc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Atea PharmaceuticalsI over a specified time horizon. Remember, high Atea PharmaceuticalsI's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Atea PharmaceuticalsI's market risk premium analysis include:
Beta 1.76 | Alpha 0.0212 | Risk 3.13 | Sharpe Ratio 0.035 | Expected Return 0.11 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Atea |
Atea PharmaceuticalsI Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Atea PharmaceuticalsI market risk premium is the additional return an investor will receive from holding Atea PharmaceuticalsI long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Atea PharmaceuticalsI. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Atea PharmaceuticalsI's performance over market.| α | 0.02 | β | 1.76 |
Atea PharmaceuticalsI expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Atea PharmaceuticalsI's Buy-and-hold return. Our buy-and-hold chart shows how Atea PharmaceuticalsI performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Atea PharmaceuticalsI Market Price Analysis
Market price analysis indicators help investors to evaluate how Atea PharmaceuticalsI stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Atea PharmaceuticalsI shares will generate the highest return on investment. By understating and applying Atea PharmaceuticalsI stock market price indicators, traders can identify Atea PharmaceuticalsI position entry and exit signals to maximize returns.
Atea PharmaceuticalsI Return and Market Media
The median price of Atea PharmaceuticalsI for the period between Fri, Jan 19, 2024 and Thu, Apr 18, 2024 is 4.0 with a coefficient of variation of 5.93. The daily time series for the period is distributed with a sample standard deviation of 0.24, arithmetic mean of 3.97, and mean deviation of 0.19. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Exercise or conversion by Foster Wayne of 33334 shares of Atea PharmaceuticalsI subject to Rule 16b-3 | 02/02/2024 |
2 | Q1 2021 Atea Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com | 02/05/2024 |
3 | SHAREHOLDER ALERT Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. and ... - Barrons | 02/13/2024 |
4 | Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 | 02/21/2024 |
5 | Atea Pharmaceuticals Inc Announces Q4 and Full Year 2023 Financial Results | 02/28/2024 |
6 | Atea Pharmaceuticals, Inc. Q4 2023 Earnings Call Transcript | 02/29/2024 |
7 | Atea Pharmaceuticals, Inc. Expected to Post Q1 2024 Earnings of Per Share | 03/06/2024 |
8 | Amylyx Pharmaceuticals, Inc. Shares Bought by GSA Capital Partners LLP - Defense World | 03/12/2024 |
9 | Atea Pharmaceuticals Shares Up 0.8 percent - Defense World | 04/03/2024 |
10 | Stonepine Capital Management LLC Trims Stake in Atea Pharmaceuticals, Inc. - MarketBeat | 04/09/2024 |
11 | Acquisition by Polsky Bruce of 34025 shares of Atea PharmaceuticalsI at 23. subject to Rule 16b-3 | 04/12/2024 |
12 | Disposition of 44367 shares by Corcoran Andrea of Atea PharmaceuticalsI subject to Rule 16b-3 | 04/17/2024 |
About Atea PharmaceuticalsI Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Atea or other stocks. Alpha measures the amount that position in Atea PharmaceuticalsInc has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Graham Number | 15.63 | 16.41 | Receivables Turnover | 7.53 | 6.69 |
Atea PharmaceuticalsI Upcoming Company Events
As portrayed in its financial statements, the presentation of Atea PharmaceuticalsI's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atea PharmaceuticalsI's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Atea PharmaceuticalsI's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Atea PharmaceuticalsI. Please utilize our Beneish M Score to check the likelihood of Atea PharmaceuticalsI's management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Atea PharmaceuticalsI
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Atea PharmaceuticalsI Backtesting, Atea PharmaceuticalsI Valuation, Atea PharmaceuticalsI Correlation, Atea PharmaceuticalsI Hype Analysis, Atea PharmaceuticalsI Volatility, Atea PharmaceuticalsI History and analyze Atea PharmaceuticalsI Performance. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Atea PharmaceuticalsI technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.